PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PRME vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PRME and CRSP is 0.49, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

PRME vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
-81.13%
-20.61%
PRME
CRSP

Key characteristics

Sharpe Ratio

PRME:

-0.79

CRSP:

-0.66

Sortino Ratio

PRME:

-1.25

CRSP:

-0.80

Omega Ratio

PRME:

0.87

CRSP:

0.91

Calmar Ratio

PRME:

-0.77

CRSP:

-0.41

Martin Ratio

PRME:

-1.47

CRSP:

-0.91

Ulcer Index

PRME:

45.60%

CRSP:

36.17%

Daily Std Dev

PRME:

84.97%

CRSP:

50.33%

Max Drawdown

PRME:

-87.50%

CRSP:

-81.61%

Current Drawdown

PRME:

-86.27%

CRSP:

-80.61%

Fundamentals

Market Cap

PRME:

$393.48M

CRSP:

$3.78B

EPS

PRME:

-$2.06

CRSP:

-$2.79

Total Revenue (TTM)

PRME:

$64.27M

CRSP:

$201.62M

Gross Profit (TTM)

PRME:

$61.70M

CRSP:

$61.70M

EBITDA (TTM)

PRME:

-$207.13M

CRSP:

-$313.08M

Returns By Period

In the year-to-date period, PRME achieves a -67.27% return, which is significantly lower than CRSP's -34.95% return.


PRME

YTD

-67.27%

1M

-3.01%

6M

-51.59%

1Y

-66.89%

5Y*

N/A

10Y*

N/A

CRSP

YTD

-34.95%

1M

-13.84%

6M

-27.60%

1Y

-32.81%

5Y*

-9.78%

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PRME vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PRME, currently valued at -0.79, compared to the broader market-4.00-2.000.002.00-0.79-0.66
The chart of Sortino ratio for PRME, currently valued at -1.25, compared to the broader market-4.00-2.000.002.004.00-1.25-0.80
The chart of Omega ratio for PRME, currently valued at 0.87, compared to the broader market0.501.001.502.000.870.91
The chart of Calmar ratio for PRME, currently valued at -0.77, compared to the broader market0.002.004.006.00-0.77-0.60
The chart of Martin ratio for PRME, currently valued at -1.47, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.47-0.91
PRME
CRSP

The current PRME Sharpe Ratio is -0.79, which is comparable to the CRSP Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of PRME and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.40JulyAugustSeptemberOctoberNovemberDecember
-0.79
-0.66
PRME
CRSP

Dividends

PRME vs. CRSP - Dividend Comparison

Neither PRME nor CRSP has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

PRME vs. CRSP - Drawdown Comparison

The maximum PRME drawdown since its inception was -87.50%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for PRME and CRSP. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%JulyAugustSeptemberOctoberNovemberDecember
-86.27%
-54.31%
PRME
CRSP

Volatility

PRME vs. CRSP - Volatility Comparison

Prime Medicine Inc. Common Stock (PRME) has a higher volatility of 24.10% compared to CRISPR Therapeutics AG (CRSP) at 19.01%. This indicates that PRME's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%JulyAugustSeptemberOctoberNovemberDecember
24.10%
19.01%
PRME
CRSP

Financials

PRME vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between Prime Medicine Inc. Common Stock and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab